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doi:10.1016/j.jmii.2011.11.007Background/Purpose: Proteus mirabilis is a common pathogen responsible for complicated
urinary tract infections (UTIs) that sometimes causes bacteremia. Most cases of P. mirabilis
bacteremia originate from a UTI; however, the risk factors for bacteremia and mortality rates
from P. mirabilis UTI have not been determined.
Methods: A retrospective, case-control study was performed between May 2008 and November
2010 to identify the risk factors and markers for P. mirabilis bacteremic UTI. Each subject in
the case group (all patients were diagnosed with P. mirabilis bacteremia from a urinary tract
source) was matched by age and gender to two subjects in the control group (patients diag-
nosed with P. mirabilis UTI but with negative blood culture results). Clinical presentation
and laboratory data were analyzed to determine the risk factors and markers of P. mirabilis
bacteremic UTI.
Results: Sixty-seven bacteremic UTIs and 124 nonbacteremic UTIs were included in this study.
Community-acquired infection (pZ 0.017), hydronephrosis (pZ 0.017), band neutrophils
accounting for >10% of the white blood cell count (pZ 0.001), hyperthermia or hypothermia
(pZ 0.047), and a serum C-reactive protein concentration >100 mg/L (pZ 0.002) were, No. 100 Tz-you 1st Road, Kaohsiung City, 807 Taiwan.
ail.com (C.-Y. Lin).
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Risk factors for P. mirabilis bacteremic UTIs 229identified as independent risk factors for P. mirabilis bacteremic UTI. Seventeen patients died
in hospital, including 11 in the bacteremic group and 6 in the nonbacteremic group. The
bacteremic group had a higher mortality rate (pZ 0.016). Bacteremic UTI (pZ 0.049), shock
(pZ 0.014), and a low body mass index (BMI) <18 kg/m2 (pZ 0.033) were identified as inde-
pendent risk factors for mortality.
Conclusion: Because bacteremic P. mirabilis UTIs are associated with higher mortality, clini-
cians should carefully manage cases that present with the risk factors for bacteremia,
including community-acquired infection, hydronephrosis, band neutrophils accounting
for >10% of the white blood cell count, hyperthermia or hypothermia, and a high level of
C-reactive protein.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Proteus mirabilis is a member of the Enterobacteriaceae
family and is a highly motile bacterium.1 Unlike the other
members of Enterobacteriaceae, P. mirabilis is not
a common pathogen that causes urinary tract infections
(UTIs) in normal hosts.2,3 In contrast, P. mirabilis is isolated
relatively frequently in complicated UTIs, such as those
that present in patients with functional or anatomical
abnormalities, especially patients with urolithiasis or
a chronic indwelling urinary catheter.4 P. mirabilis is well
known for its ability to produce urease, which generates
ammonia and elevates the pH of the urine to >7.2.5
Calcium and magnesium crystallization in the urine of
alkaline pH blocks the catheter lumen and causes acute
urinary retention and the development of bacteriuria and
other ascending infections, thereby leading to pyelone-
phritis, bacteremia, and shock.6
P. mirabilis is susceptible to b-lactams, aminoglyco-
sides, fluoroquinolones, and trimethoprim/sulfamethox-
azole, but is resistant to nitrofurantoin and tetracycline.7
In recent years, a trend has been observed where
Enterobacteriaceae species, including P. mirabilis, show
increased resistance to several antimicrobial agents.8,9 This
increased resistance to antimicrobial agents has led not
only to a changes in antimicrobial therapies, but also to
poor prognoses and an increase in the mortality rate of
hospitalized patients.10
Although the risk factors and clinical outcomes of
bloodstream infections originating from extended spectrum
b-lactamase (ESBL)-positive Escherichia coli and Klebsiella
pneumoniae have been investigated recently,11e14 bacter-
emic UTIs caused by P. mirabilis are relatively uncommon
and, to date, have been less thoroughly studied.15e17
Furthermore, previous studies show that patients with
bactermic UTIs present with more severe systemic inflam-
matory response syndrome (SIRS) and higher mortality rates
than patients without bacteremia.18,19
Thus, we conducted a retrospective, matched, case-
control study in patients with P. mirabilis bacteremic UTIs.
The aims of our study were to (1) determinate the relative
risk factors of P. mirabilis bacteremic UTIs, (2) investigate
the risk factors related to mortality, and (3) compare the
resistance profiles of P. mirabilis between these two groups
of patients.Methods
Study setting and population
Our retrospective, matched, case-control study compares
bacteremic and nonbacteremic patients with P. mirabilis
UTIs who were recruited from the Kaohsiung Medical
University Hospital (KMUH), a 1600-bed medical center
located in Kaohsiung City in southern Taiwan.
Patients were retrospectively identified from the micro-
biology databases at KMUH and data were prospectively
collected from May 1, 2008 through November 30, 2010.
Medical records were reviewed by two infectious disease
specialists. Data on the following variables were collected:
age, gender, date of admission, diagnosis, outcome, and
in vitro antimicrobial susceptibility. This study protocol was
approved by the Institutional Review Board of KMUH.
Determination of case controls
Patients from whom a urinary culture was obtained, but not
a blood culture, and those younger than 18 years of age
were excluded. Blood cultures were collected from all
enrolled patients. Patients with a positive blood culture
from a source other than a UTI, such as a decubitus ulcer or
an intra-abdominal infection, were also excluded from this
study. Patients with a UTI and bacteremia due to P. mir-
abilis were identified as cases, while patients with a UTI
and no bacteremia were identified as controls. Cases and
controls were matched for age (5 years) and sex; the
case:control ratio was 1:2.
Case definition
P. mirabilis bacteremic UTIs were defined by a positive
urine culture with >105 colony-forming units (cfu)/mL and
isolation of the same strain of P. mirabilis from both the
urine and blood from the same patient at the same time.20
Control P. mirabilis UTI cases without bacteremia were
defined by a positive urine culture in the presence of >105
cfu/mL accompanied by one of the following: (1) signs of
a UTI, such as fever, dysuria, increased frequency of
micturition, back or flank pain, or costovertebral angle
tenderness; (2) pyuria21; or (3) a nonspecific decline in
230 C.-Y. Chen et al.functions or symptoms that could not be attributed to an
obvious source of infection other than UTI.22
A patient was considered febrile when the highest
recorded tympanic temperaturewas>38.0 C on the day the
blood culture was collected.23 Kidney failure was defined as
a creatinine level >1.5 mg/dL,24 and co-morbid conditions
(such as cirrhosis, diabetes, etc.) or immunocompromised
status were ascertained according to the patient’s medical
records and Charlson’s score;25 these findings were reviewed
by two infectious disease specialists. Nosocomial infections
were defined as (1) infections occurring more than 48 hours
after hospital or emergency department admission or (2) if
patients were referred from another hospital or healthcare
facility.26 Chronic or long-term urinary catheterization was
defined as catheterization for more than 7 days prior to
specimen collection for bacterial culturing.27 A urological
abnormality was defined as either the presence of urinary
tract obstructions, urethral strictures, urolithiasis, benign
prostate hyperplasia, congenital abnormalities, or func-
tional problems such as neurogenic bladder or vesicoure-
teral reflux. A shock episode was defined as a systolic
pressure <90 mmHg or the use of inotropic agents to main-
tain blood pressure for at least 1 hour.
Imaging studies of every case were reviewed whenever
possible, and abdominal computed tomography (CT) scan,
kidney, ureter, and bladder (KUB) x-rays, or sonographic
results were all recorded. We tried to identify whether
hydronephrosis or urolithiasis was present in each case. The
initial antimicrobial therapy was considered appropriate if
at least one antimicrobial agentwas active in vitro according
to Clinical and Laboratory Standards Institute (CLSI) guide-
lines and was administrated within 48 hours after all samples
were collected for culturing.27 During the study period,
a patient was considered to have had two individual episodes
when there was complete remisson of fever, leukocytosis,
and local signs of infection more than 1 month after the
discontinuation of any antimicrobial therapy that was
administered to treat the first UTI episde.28
Microbiological methods
Blood culture samples were collected in aerobic and
anaerobic bottles and were cultured using the BACT/Alert
3D system (Becton Dickinson Microbiology Systems, Sparks,
MD, USA). The Vitek 2 System (Biomerieux, Durham, NC,
USA) was used to identify and determine the antibiotic
susceptibility of the P. mirabilis isolates. Susceptibility
results were interpreted as sensitive, intermediate, or
resistant to antibiotics, according to CLSI criteria.29
Multi-drug resistant (MDR) isolates were defined as
isolates resistant to or with intermediate susceptibility to
more than three classes of the following antimicrobial
groups: (1) ampicillin, amoxicillin/clavulanate, or piper-
acillin/tazobactam; (2) cefuroxime, ceftriaxone, or cefe-
pime; (3) carbapenems; (4) ciprofloxacin or levofloxacin;
(5) gentamicin or amikacin; and (6) cotrimoxazole.30
Statistical analysis
All statistical analyses were performed using SPSS version
14.0 (SPSS Inc., Chicago, IL, USA). Data were analyzed usingthe Student t test for continuous variables and Fisher’s
exact test and Pearson’s c2 test for categorical variables.
Significance was set at p< 0.05 using two-sided compari-
sons. All significant (p< 0.05) variables that were identified
by univariate analysis were further analyzed by multivari-
able analysis for logistic regression.Results
During the study period, a total of 740 P. mirabilis bacter-
emic and nonbacteremic UTI cases were evaluated, but
only 656 cases remained after the exclusion of isolates from
patients under 18 years of age. The causes of the bacter-
emia in 18 of the 85 cases of P. mirabilis bacteremia were
thought to be unrelated to the initial UTI. Therefore, 67
episodes were included in the bacteremic group. Among
571 cases of P. mirabilis-induced bacteriuria, 447 episodes
lacked concurrent blood culture data or were suspected to
reflect colonization and were therefore excluded. Cases
were matched, as much as possible, for sex and age to 124
controls (bacteriuric episodes with definitively negative
blood culture results) in a 1:2 ratio. A total of 191 cases
were included in our study, including 67 in the bacteremic
group (35.07%) and 124 (64.9%) in the nonbacteremic group.
Six patients had two episodes each during the study period
(i.e., a total of 191 episodes in 185 patients).
The demographic and clinical characteristics of the
patients are shown in Table 1. Of 191 episodes, 60 patients
were admitted to intensive care units (ICUs). Among these,
24 were in the bacteremic group and 36 were in the non-
bacteremic group. Of these 191 episodes, 147 (77.0%) cases
received imaging studies. Nearly half of the cases (49.0%)
underwent abdominal sonography, and in 24.6% of cases the
patient underwent an abdominal CT scan. In 2.6% of cases,
the patient received only a KUB examination.
Univariate analysis revealed that bacteremic P. mirabilis
UTIs are more common in patients with community-
acquired infections than in those with nosocomial-
acquired infections (41.9% vs. 22.4%, pZ 0.011). Hydro-
nephrosis appeared in 43.3% of patients in the bacteremic
group, but in only 12.1% of those the nonbacteremic group
(p< 0.001). Comparing the bacteremic group with the
nonbacteremic group, a higher prevalence of urolithiasis
was found in the P. mirabilis bacteremic group (44.8% vs.
24.2%, pZ 0.006). Chronic urinary catheterization was less
common in patients with community-acquired infections
(26.6% vs. 62.7%, p< 0.001) (data not shown). There was no
obvious difference in the duration of preadmission symp-
toms between these two groups (pZ 0.903) (Table 1).
Regarding the clinical presentation, the bacteremic group
tended to present with hyperthermia (body temperature
>38 C) or hypothermia (body temperature <36 C) (76.1%
vs. 56.3%, pZ 0.011), higher blood urea nitrogen (BUN)
levels (average 40.44 47.57 mg/dL vs. 25.37 26.37 mg/
dL, pZ 0.020), and azotemia (58.2% vs. 41.1%, pZ 0.035).
A band neutrophil count >10% of the white blood cell (WBC)
count was more commonly found in the bacteremic group
(22.4% vs. 6.5%, pZ 0.003). There was no statistically
significant difference in terms of the presence of a WBC
count >12,000 /mL between the bacteremic and
nonbacteremic groups (64.2% vs. 50.8%, pZ 0.105).
Table 1 Demographic and clinical characteristics of patients with bacteremic and nonbacteremic UTIs caused by P. mirabilis
Demographic and clinical
manifestations
No. (%) of episodes Odds ratio (95% CI) p-value
Bacteremic UTI
nZ 67 (%)
Nonbacteremic UTI
nZ 124 (%)
Age (y, mean SD) 68.16 16.85 70.96 16.09 d 0.262
Sex (female) 41 (61.2) 81 (65.3) 0.84 (0.43e1.62) 0.680
Body mass index <18 16 (23.9) 24 (19.4) 1.31 (0.64e2.67) 0.584
Recent hospitalizationa 38 (56.7) 75 (60.5) 0.86 (0.45e1.64) 0.725
Hospital stay (d, mean SD) 19.47 22.33 17.44 17.49 d 0.502
Clinical condition
Diabetes mellitus (type 2) 17 (25.4) 44 (35.5) 0.62 (0.36e1.20) 0.205
Kidney failureb 17 (25.4) 30 (24.1) 1.07 (0.51e2.23) 0.996
Liver cirrhosis 3 (4.5) 4 (3.2) 1.41 (0.24e7.73) 0.698
COPD 9 (13.4) 13 (10.5) 1.32 (0.53e3.20) 0.710
Malignancy 11 (16.4) 24 (19.4) 0.82 (0.37e1.80) 0.761
Cerebral vascular disease 28 (41.8) 61 (49.2) 0.74 (0.41e1.35) 0.408
Bedridden 34 (50.7) 79 (63.7) 0.59 (0.32e1.12) 0.113
Charlson’s score SD 6.12 3.87 6.87 4.036 d 0.215
Source of infection
Nosocomial-acquired infectionc 15 (22.4) 52 (41.9) 0.40 (0.20e0.79) 0.011*
Urinary tract abnormalitiesd 47 (70.1) 70 (56.5) 1.81 (0.96e3.41) 0.089
Hydronephrosis 29 (43.3) 15 (12.1) 5.55 (2.69e11.49) <0.001*
Urolithiasis 30 (44.8) 30 (24.2) 2.54 (1.35e4.78) 0.006*
Chronic urinary catheterizatione 23 (34.3) 52 (41.9) 0.72 (0.39e1.34) 0.503
Shock 21 (31.3) 28 (22.6) 1.57 (0.80-3.05) 0.250
ICU admission 24 (35.8) 36 (29.0) 1.36 (0.73e2.57) 0.423
Inotropic agent use 20 (29.9) 23 (18.5) 1.87 (0.94e3.73) 0.109
Preadmission history
Symptom onset prior to
medical care (d, mean SD)
2.29 3.66 2.00 2.16 d 0.903
*p< 0.05.
Abbreviations: CI, confidence interval; SD, standard deviation; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit.
a Recent hospitalization: recent refers to hospitalization within the past year.
b Kidney failure: defined as a creatinine level >1.5 mg/dL.24
c Nosocomial infection: (1) infections occurring more than 48 hours after hospital admission or after emergency department admission,
or (2) those who were referred from another hospital or healthcare facility.26
d Urinary tract abnormalities: presence of urinary tract obstruction, urethral strictures, urolithiasis, benign prostatic hypertrophy,
congenital abnormalities, or functional problems such as neurogenic bladder or vesicoureteral reflux.
e Chronic urinary catheterization was defined as a catheter that had been in place for more than 7 days.27
Risk factors for P. mirabilis bacteremic UTIs 231A higher C-reactive protein concentration was more
common in the bacteremic group (160.52 106.67% vs.
77.59 74.19, p< 0.001). (Table 2).
The significant risk factors that were identified by
univariate analysis were further analyzed by multivariate
logistic regression. This analysis was able to identify the
community source (adjusted odds ratio: 2.70; 95%
CI:1.19e6.09; pZ 0.017), hydronephrosis (adjusted odds
ratio: 3.22; 95% CI: 1.24e8.39; pZ 0.017), WBC band
neutrophils accounting for >10% of the WBC count
(adjusted odds ratio: 6.09; 95% CI: 2.07e17.94; pZ 0.001),
hyperthermia or hypothermia (adjusted odds ratio: 2.21;
95% CI: 1.01e4.82; pZ 0.047), and C-reactive protein level
>100 mg/L (adjusted odds ratio: 3.11; 95% CI: 1.51e6.39;
pZ 0.002) as independent factors associated with an
increased risk of bacteremia in patients with a P. mirabilis
UTI (Table 3).Clinical outcomes
Seventeen patients died during their hospitalizations. The
in-hospital mortality rate of P. mirabilis UTI was 8.9%.
Among the 17 patients who died (total), 11 were in the
bacteremic group and 6 were in the nonbacteremic group.
Univariate analysis showed that a higher mortality rate was
significantly associated with P. mirabilis bacteremia (16.4%
vs. 4.8%, pZ 0.016), a stay in the ICU (76.5% vs. 27.0%,
p< 0.001), the occurrence of a shock episode (82.4% vs.
20.1%, p< 0.001), vasopressor use (64.7% vs. 18.4%,
p< 0.001 ), C-reactive protein concentration >100 mg/dL
(70.6% vs. 41.4%, pZ 0.039), and a body mass index (BMI)
<18.0 (47.1% vs. 18.4%, pZ 0.014). Risk factors identified
by univariate analysis were entered into a multivariate
logistic regression model, and this analysis identified
bacteremia (adjusted odd ratios: 3.52; 95% CI: 1.00e12.40;
Table 2 Laboratory findings and clinical presentation of P. mirabilis UTIs, with and without bacteremia
Laboratory findings No.(%) of Episodes Odds ratio (95% CI) p-value
Bacteremic UTI
nZ 67
Non-bactermic UTI
nZ 124
Body temperature >38C or <36.0C 51 (76.1) 70 (56.3) 2.45 (1.26e4.78) 0.011*
MAP (mean, mmHg SD) 131.44 33.95 128.42 29.64 d 0.539
Pulse rate (mean, beats/min SD) 103.18 24.42 98.97 23.93 d 0.266
Azotemia 39 (58.2) 51 (41.1) 1.99 (1.09e3.65) 0.035*
Creatinine (mg/dL, mean SD) 1.59 1.39 1.25 1.21 d 0.081
White blood cell count (103/mL, mean SD) 16.20 9.21 12.146 5.956 d 0.002
White blood cell count (> 12,000/mL), 43 (64.2) 63 (50.8) 1.74 (0.94e3.19) 0.105
Band >10 % 15 (22.4) 8 (6.5) 4.18 (1.67e10.53) 0.003*
C-reactive protein (mg/L, mean SD) 160.52 106.67 77.59 74.19 d <0.001*
*p< 0.05.
Abbreviations: CI, confidence interval; MAP, mean arterial pressure; SD, standard deviation.
232 C.-Y. Chen et al.pv0.049), shock episode (adjusted odds ratio: 9.36; 95% CI:
1.58e55.46; pZ 0.014), and an extremely low BMI (< 18.0)
(adjusted odds ratio: 3.8; 95% CI: 1.12e13.00; pZ 0.033) as
factors associated with a high risk of in-hospital mortality
(Table 4).In vitro antimicrobial resistance profiles
MDR P. mirabilis strains were more frequently isolated from
the nonbacteremic group than from the bacteremic group
(but this finding was not statistically significant [50.0 % vs.
35.8%; pZ 0.084]). MDR P. mirabilis strains were more
common in patients with nosocomial infections that were
obtained from either a hospital or another healthcare
facility (p< 0.001) (data not shown). Univariate analysis
revealed that the percentage of P. mirabilis isolates
susceptible to the first-generation application of cephalo-
sporin and fluoroquinolone was significantly lower in the
nonbacteremic group (71.8% vs. 88.1%, pZ 0.017; 58.1% vs.Table 3 Multivariate analysis of factors associated with P. mira
Variable Odds ratio Univariable
(95% CI)
Community-acquired 2.51 (1.26e5.00)
Hydronephrosis 5.55 (2.69e11.49)
Urolithiasis 2.54 (1.35e4.78)
Bands >10% of white
blood cell count
4.18 (1.67e10.53)
Body temperature
>38.0C or
<36.0C
2.45 (1.26e4.78)
BUN >20 mg/dL 1.99 (1.09e3.65)
C-reactive protein
>100 mg/L
4.02 (2.14e7.51)
*p< 0.05.
Adjusted odds ratio: variables with p-values <0.05 were further analy
expected 95% CI and adjusted odds ratio.
BUN, blood urea nitrogen; CI, confidence interval.83.6%, pZ 0.001, respectively). Carbapenems were fully
active in vitro in both groups. (Table 5) The percentage of
patients who received the appropriate initial antibiotic
treatment was smaller in the group infected with MDR
strains than in the group infected with non-MDR strains
(72.1% vs. 89.5%, pZ 0.004); however, MDR P. mirabilis
infection was not associated with a poor clinical outcome
(41.2% vs. 45.4%, pZ 0.937). The bacteremic group was
treated with antibiotics for an average of 16.00 6.22
days.
We compared the preadmission histories of both groups.
The use of antibiotics before culture collection and the
duration of symptoms prior to receiving medical care were
recorded. Difference in the use of antimicrobial agents to
treat the bacteremic and nonbacteremic groups was of
borderline significance (57.9% vs. 42.1%, pZ 0.052). From
the onset of symptoms to the initiation of medical care, the
difference in average duration in bacteremic and non-
bacteremic groups was not statistically significant
(2.29 3.66 vs. 2.00 2.16 days, pZ 0.903) (Table 1).bilis bacteremic urinary tract infections
p-value Adjusted
Odds ratio
Multivariable
(95% CI)
p-value
0.01 2.70 (1.19e6.09) 0.017*
<0.001 3.22 (1.24e8.39) 0.017*
0.006 1.13 (0.46e2.76) 0.792
0.003 6.09 (2.07e17.94) 0.001*
0.011 2.21 (1.01e4.82) 0.047*
0.035 1.78 (0.88e3.61) 0.111
<0.001 3.11 (1.51e6.39) 0.002*
zed for multivariable analysis for logistic regression, yielding the
Table 4 Independent risk factors associated with P. mirabilis UTI survival (the odds ratio is for mortality)
Variable Death
(nZ 17)
Survival
(nZ 174)
Odds ratio
(95% CI)
Adjusted
odds ratio (95% CI)
p-value
Age (y) 71.47 18.38 69.83 16.26 0.70 d d
Sex (female) 10 (58.8) 112 (64.4) 0.79 (0.29e2.18) d d
Bacteremia 11 (16.4) 56 (32.21) 3.86 (1.36e10.97)* 3.52 (1.00e12.40)* 0.049*
ICU admission 13 (76.5) 47 (27.0) 8.77 (2.72e28.57)* 1.85 (0.30e11.49) 0.511
Shock 14 (82.4) 35 (20.1) 18.52 (5.05e66.60)* 9.36 (1.58e55.46)* 0.014*
Vasopressor use 11 (64.7) 32 (18.4) 8.13 (2.80e23.80)* 2.00 (0.28e5.60) 0.764
Appropriate initial
antimicrobial therapya
14 (82.4) 142 (81.6) 1.18 (0.29e3.88)
COPD 2 (11.8) 20 (11.5) 1.02 (0.22e4.83)
Cerebral vascular disease 9 (52.9) 80 (46.0) 1.32 (0.49e3.58)
Bedridden 14 (82.4) 99 (56.9) 3.53 (0.98e12.80)
Nosocomialb 7 (41.2) 60 (34.5) 1.33 (0.48e3.68)
Diabetes mellitus 6 (35.3) 55 (31.6) 1.18 (0.40e3.35)
Hydronephrosis 1 (5.9) 43 (24.7) 0.19 (0.002e1.30)
Kidney failurec 7 (41.1) 40 (22.9) 2.35 (0.75e7.26)
Urolithiasis 3 (17.6) 57 (32.8) 0.44 (0.12e1.59)
Chronic urinary
catheterizationd
8 (47.1) 67 (89.3) 1.42 (0.52e3.86)
C-reactive protein >100 mg/L 12 (70.6) 72 (41.4) 3.40 (1.15e10.10)* 0.78 (0.22e2.81) 0.700
Body temperature >38.0C or
<36C
9 (52.9) 112 (64.4) 0.62 (0.23e1.69)
Multidrug resistant isolatese 7 (41.2) 79 (45.4) 0.85 (0.36e2.31)
BMI <18.0 8 (47.1) 32 (18.4) 3.94 (1.41e10.99)* 3.80 (1.12e13.00)* 0.033*
*p < 0.05.
Adjust odd ratio: univariables with p-values < 0.05 were further analyzed by multivariable analysis for logistic regression, yielding the
expected 95% CI and adjusted odd ratio.
BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease.
a Considered appropriate if at least one antimicrobial agent was active in vitro according to CLSI guidelines and administrated within
48 hours after all samples were collected for culturing.
b Nosocomial infection: (1) infections occurring more than 48 hours after hospital admission or after emergency department admission,
or (2) those who were referred from another hospital or healthcare facility.26
c Kidney failure is defined as a creatinine level >1.5 mg/dL.
d When the catheter had been maintained for more than 7 days.
e Multidrug resistant isolates are defined as resistant or intermediately susceptible to more than three classes of the flowing anti-
microbial groups:30 (1) ampicillin, amoxicillin/clavulanate, or piperacillin/tazobactam; (2) cefuroxime, ceftriaxone, and cefepime; (3)
carbapenems; (4) ciprofloxacin or levofloxacin; (5) gentamicin or amikacin; (6) cotrimoxazole.
Risk factors for P. mirabilis bacteremic UTIs 233Discussion
Our analysis identified independent factors associated with
the increased risk of bacteremia in patients with P. mir-
abilis UTIs. These independent risk factors include the
following: community-acquired infection, hydronephrosis,
the increased presence of band neutrophils accounting for
>10% of the WBC count, hyperthermia or hypothermia, and
a C-reactive protein level >100 mg/L. In a previous survey,
bacteremic UTI s were often associated with longer hospi-
talizations, more severe complications, and higher
mortality rates compared with nonbacteremic UTIs.31,32
Several studies have surveyed the clinical presentation
and laboratory manifestations of bacteremic UTIs. Leibovici
et al investigated 247 older patients (median age: 75 years)
and found that a high serum creatinine level, high WBC
count, hyperthermia, diabetes mellitus, and low serum
albumin level are more common in patients with bacter-
emic UTIs caused by various kinds of pathogens.32 In
contrast, Bahagon et al showed no statistically significantdifference between diabetes mellitus, chronic kidney
disease (CKD), or immunocompromised status as risk
factors for bacteremic UTI, but both of their studies iden-
tified severe SIRS reactions as more common in the
bacteremic group;32,33 however, the leading causative
pathogen among the patients in these studies was E. coli,
and their analysis was performed in patients with different
pathogens. The risk factors for P. mirabilis bacteremic UTI
have not been fully elucidated.17,34,35
Compared with UTIs caused by E. coli, UTIs caused by
Proteus spp. are often more severe and associated with
a higher incidence of pyelonephritis. In Proteus spp UTIs,
the urine pH is often >7.2. The majority of the bloodstream
infections caused by Proteus spp. originate from a UTI and
are often associated with urinary catheters. Consistent
with previous studies,32,36 our study demonstrates that
hydronephrosis, band neutrophils accounting for >10% of
the WBC count, hyperthermia or hypothermia, a severe SIRS
reaction, and a high C-reactive protein concentration are
more common in P. mirabilis bacteremic UTIs; however,
Table 5 Antimicrobial sensitivity profiles
Antimicrobial agents No. (%) of Episodes Odd ratio (95% CI) p-value
Bacteremic UTI
nZ 67
Non-bacteremic UTI
nZ 124
Cephalosporins
First generation 59 (88.1) 89 (71.8) 2.90 (1.26e6.67) 0.017*
Second generationa 63 (94.0%) 103 (83.1%) 3.22 (1.05e9.80) 0.055
Third generationb 59 (88.1%) 95 (76.6) 2.25 (0.96e5.26) 0.086
Fourth generationc 59 (88.1%) 95 (76.6) 2.25 (0.96e5.26) 0.086
Extended penicillind 26 (38.8) 36 (29.0) 1.550 (0.83e2.90) 0.224
Cotrimoxazole 23 (34.3) 36 (29.0) 1.28 (0.68e2.42) 0.554
Aminoglycosidee 46 (68.7) 66 (53.2) 1.93 (1.03e3.60) 0.056
Carbapenemf 67 (100) 124 (100) d d
Fluoroquinoloneg 56 (83.6) 72 (58.1) 3.68 (1.76e7.69) 0.001*
Multidrug- resistant isolatesh 24 (35.8) 62 (50.0) 1.79 (0.97e3.30) 0.084
a Second-generation cephalosporin: cefuroxime or cefmetazole.
b Third-generation cephalosporin: ceftriaxone or ceftazidime.
c Fourth-generation cephalosporin: cefepime.
d Extended penicillin: ampicillin, amoxicillin/clavulanate, or piperacillin/tazobactam.
e Aminoglycoside: gentamicin or amikacin.
f Carbapenem: imipenem/meropenem/ertapenem.
g Fluoroquinolone: ciprofloxacin or levofloxacin.
h Multidrug-resistant isolates are defined as resistance or intermediate susceptibility to more than three classes of the following
antimicrobial groups:30 (1) ampicillin, amoxicillin/clavulanate, or piperacillin/tazobactam; (2) cefuroxime, ceftriaxone, or cefepime;
(3) carbapepenems; (4) ciprofloxacin or levofloxacin; (5) gentamicin or amikacin; (6) cotrimoxazole.
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diabetes mellitus, chronic obstructive pulmonary disease
(COPD), or immunocompromised status. Furthermore, our
results show that bacteremic P. mirabilis UTIs are more
common in patients with community-acquired infections.
Preadmission history of antimicrobial treatments and
duration of symptoms prior to the onset of medical care of
both groups were investigated, but no statistically signifi-
cant difference was confirmed. In contrast, higher rates of
urolithiasis and hydronephrosis were noted in patients with
community-acquired infections in our cohort. At the same
time, a lower proportion of chronic urinary catheterization
was also noted in the community-acquired group. Thus,
patients with functional urological problems, such as
neurogenic bladder or urinary retention, are at a higher risk
of developing hydronephrosis and urolithiasis formation and
encrustation. Encrustation further blocks the lumen,
obstructs flow, and causes vesicoureteral reflux, thereby
inducing an ascending infection that can further develop
into pyelonephritis, bacteremia, and shock. This may
explain why the bacteremic P. mirabilis UTIs are more
common in patients with community-acquired infections.
In our study, 17 patients died (8.9%), 11 of whom were in
the bacteremic group and 6 of whom were in the non-
bacteremic group. Multivariate analysis using logistic
regression showed that bacteremic UTI, shock, and an
extremely low BMI are independent risk factors of
mortality. In our study, patients with P. mirabilis bacter-
emia had a higher rate of mortality than nonbacteremic
patients. This finding is similar to findings in other studies
on Enterobacteriaceae-causing bacteremic UTIs.18,36 Two
previous studies have pointed out that bacteremic UTI in
patients with a low serum albumin level and a severe SIRSreaction tended to be associated with poor clinical
outcomes.28,36 Our finding that an extremely low BMI is an
independent risk factor for poor clinical outcomes has also
been reported in previous studies.37,38 The reason why we
did not investigate an association between the serum
albumin level and clinical outcome was because of missing
clinical data from some of our patients. Our results show
that an extremely low BMI is similar to a low serum albumin
level in terms of its usefulness as a predictor of a poor
clinical outcome. Sometimes a low BMI is superior to
albumin as a clinical predictor because BMI may be more
readily determined by primary care clinicians.
Our study demonstrates that isolates of P. mirabilis in
nonbacteremic UTIs are less susceptible to first-generation
cephalosporin and fluoroquinolone than isolates of P. mir-
abilis in bacteremic UTIs. In comparison with non-MDR
isolates, more patients infected with MDR strains did not
receive the appropriate initial antibiotic treatment;
however, MDR P. mirabilis infections were not associated
with poor clinical outcomes (Table 4), and this finding has
been noted in other studies.30,39 Endimiani et al reported
that ESBL-producing P. mirabilis bloodstream infections are
associated with poor outcomes.28 Differences between
these results may be because MDR P. mirabilis isolates were
less common in the bacteremic group in our cohort.
The most important limitation of this study is that the
number of cases was small. Another limitation is that our
study is a retrospective study, and the preadmission histo-
ries of each patient (such as the classes of antibiotics used
before and during treatment) were based primarily on
statements provided by the patients and their families and
are, therefore, difficult to interpret. Finally, missing data
on serum albumin levels in some of our patients led to
Risk factors for P. mirabilis bacteremic UTIs 235difficulty evaluating the association between serum
albumin levels and patient’s clinical outcome.
In conclusion, the independent risk factors for
bacteremia-complicating P. mirabilis UTIs were determined
to be the following: community-acquired infection, hydro-
nephrosis, SIRS reaction, band neutrophils accounting for
>10% of the WBC count, and a high C-reactive protein level.
Bacteremic UTIs, shock, and low BMI were associated with
poor clinical outcomes. We recommend that patients with
the clinical presentation and risks factors mentioned above
undergo further radiologic imaging studies, such as
abdominal sonography or a CT scan. Further studies that
include a greater number of cases may be necessary.Conflicts of interest
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